J&J Expects A Commercial COVID-19 Vaccine Market By Late 2022/2023

The company is currently providing its COVID-19 vaccine on a not-for-profit basis but expects that will change as the pandemic phase of the crisis abates.

Sales growth concept
J&J reported steady Q3 sales growth • Source: Alamy

More from Earnings

More from Business